Market Place
Sourcing Support
Molecular Partners Rethinks Dosing After Suboptimal Cancer Trial Results
27 Aug 2024 //
FIERCE BIOTECH
Molecular Partners begins acute myeloid leukemia therapy trial
17 Jan 2023 //
CLINICAL TRIALS ARENA
Molecular Partners Reports Corporate Highlights and H1 2022 financials
25 Aug 2022 //
PRESS RELEASE
Molecular Partners: Robbins LLP Reminds Investors of Lead Plaintiff Deadline
22 Jul 2022 //
GLOBENEWSWIRE
Interim Management Statement Q1 2022 Of Molecular Partners
12 May 2022 //
PRESS RELEASE
Molecular Partners To Participate In Upcoming Healthcare Investor Conferences
11 May 2022 //
PRESS RELEASE
Molecular Partners CEO, Elected President Of The Swiss Biotech Association
03 May 2022 //
PRESS RELEASE
Amgen opts to DARP-out after seeing Molecular Partners data
27 Apr 2022 //
FIERCEBIOTECH
Molecular Partners Provides Update on Ensovibep on Novartis Quarterly Earnings
26 Apr 2022 //
PRESS RELEASE
Molecular falls as partner Novartis says more data needed ensovibep
26 Apr 2022 //
SEEKINGALPHA
Novartis seeks FDA EUA for Covid-19 antiviral candidate ensovibep
11 Feb 2022 //
PHARMACEUTICAL-TECHNOLOGY
Molecular Partners Finalizes License Agreement With Novartis For Ensovibep For Covid-19
18 Jan 2022 //
PRESS RELEASE
Molecular Partners Reports Disclosure Of Major Shareholder As Per Swiss Stock Exchange Regulations
13 Jan 2022 //
PRESS RELEASE
Novartis snaps up rights to Covid-19 antiviral after seeing mid-stage results
10 Jan 2022 //
ENDPTS
Molecular Partners To Present At Upcoming Healthcare Investor Conferences
05 Jan 2022 //
PRESS RELEASE
Novartis tags Molecular Partner for next radioligand play in $560M biobucks deal
14 Dec 2021 //
FIERCEBIOTECH
Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant
11 Dec 2021 //
GLOBENEWSWIRE
Molecular Partners to suspend subject enrolment in Phase III Covid-19 trial
17 Nov 2021 //
CLINICALTRIALSARENA
MOLECULAR PARTNERS PRESENT DATA DEMONSTRATING SUCCESSFUL INHIBITION OF COVID19
20 Oct 2021 //
PRESS RELEASE
AbbVie ditches late-stage eye drug license, collab with Molecular Partners
10 Aug 2021 //
ENDPTS
Molecular Partners prices IPO, falling short of original goal
16 Jun 2021 //
FIERCEBIOTECH
Molecular Partners Announces First Patient Dosed in ACTIV-3 Trial
14 Jun 2021 //
MOLECULAR PARTNERS
Novartis, Molecular Partners launch global study of novel COVID-19 drug
28 May 2021 //
PMLIVE
Novartis and Molecular Partners announce start of EMPATHY clinical trial
27 May 2021 //
NOVARTIS
Novartis, Molecular Partners start global trial for COVID drug
27 May 2021 //
FIERCEBIOTECH
Molecular Partners and Novartis Announce Inclusion of COVID-19 Antiviral
15 Mar 2021 //
MOLECULEPARTNER
After Mesoblast COVID-19 flop, Novartis taps Molecular Partners
15 Mar 2021 //
FIERCEBIOTECH
Molecular Partners to Present Data from Localized Immune Agonist (MP0317)
11 Mar 2021 //
YAHOO
Molecular Partners begins patient dosing in phase 1 study of MP0420
24 Nov 2020 //
PHARMABIZ
Molecular Partners Doses First Cohort in Phase 1 Trial of COVID-19 DARPin®
23 Nov 2020 //
PRESSRELEASE
Molecular Partners jumps after Novartis deal for potential COVID-19 drugs
29 Oct 2020 //
REUTERS
Novartis announces collaboration with Molecular Partners
28 Oct 2020 //
PRESS RELEASE
Novartis taps Molecular Partners to defeat COVID-19
27 Oct 2020 //
FIERCE BIOTECH
Molecular Partners` DARPin molecules Show preclinical action against COVID-19
06 Oct 2020 //
SEEKING ALPHA
Molecular Partners completes manufacturing runs in bid for COVID-19 drug
15 Sep 2020 //
REUTERS
Molecular Partners gets Swiss gov`t payment for COVID candidate
11 Aug 2020 //
REUTERS
Molecular Provides Update of European & Japanese Filings of Abicipar Pegol
20 Jul 2020 //
MOLECULARPARTNERS
Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies
15 Oct 2019 //
BIOSPACE
Allergan & Molecular Partners Announce Result from MAPLE study of Abicipar pegol
02 Apr 2019 //
PR NEWSWIRE
Amgen, Molecular Partners Enter Immunotherapy Alliance
28 Dec 2018 //
CONTRACT PHARMA
